Tepezza (teprotumumab, Amgen), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of eligible

Eye care professionals may need to ask patients complaining about digital eye strain for specifics on screen time, with a new study finding that

Marcolin and Marchon Eyewear, both part of VSP Vision, have announced a series of global leadership appointments.

SILMO Paris will return to Paris Nord Villepinte from 24–27 September 2027.